Begin patient enrollment in the BB-301 clinical trial for OPMD

Deadline passed; outcome being checked

What the company said

“Clinical trial to begin enrollment over the next 18-to-22 months”

SourceBenitec Biopharma Inc. Form 8-K press release, 2021-02-24
FilingSEC filing index
Deadline as statedover the next 18-to-22 months
Deadline used31 Dec 2022, the last day of the stated period
TypeProject
Permanent referenceKI-C-2021-BNTC-024325
Cite as https://keptindex.org/c/KI-C-2021-BNTC-024325/ — this address never changes.

The deadline has passed. We check for public evidence starting 30 days after the deadline, and repeat the check if nothing clear turns up.

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Version 1 · original · stated 24 Feb 2021

Deadline 31 Dec 2022 (“over the next 18-to-22 months”)
Version 2 · stated 5 Oct 2026

Deadline 30 Jun 2027 (“mid-2027”) · wording expected

“Patient enrollment is planned to begin in mid-2027.”
Source for this version

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Commitment recordedThe company's words were matched word for word against the filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you Benitec Biopharma Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.